Full Text Journal Articles by
Author Christophe Borg

Advertisement

Find full text journal articles






How to Choose the Right Treatment for Patients With Advanced Squamous Cell Carcinoma in the Absence of a Comparative Randomized Clinical Trial.

Stefano Kim, Dewi Vernerey, Christophe Borg,

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, :JCO2002137]

Cited: 0 times

View full text PDF listing >>



Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials.

Laurie Spehner, Stefano Kim, Angélique Vienot, Eric François, Bruno Buecher, Olivier Adotevi, Dewi Vernerey, Syrine Abdeljaoued, Aurélia Meurisse, Christophe Borg,

Docetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous cell carcinoma (SCCA), as demonstrated by the Epitopes-HPV02 study results. Here, we analyzed the impact of DCF regimen and the prognostic value of adaptive immune responses and immunosuppressive cells in SCCA patients included in two prospective ... Read more >>

Int J Mol Sci (International journal of molecular sciences)
[2020, 21(18):]

Cited: 0 times

View full text PDF listing >>



Advertisement

Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift?

Florian Seckler, Alexandre Doussot, Prudence Colpart, Célia Turco, Paul Calame, François Aubin, Marie Paule Algros, Christophe Borg, Charlée Nardin, Bruno Heyd,

J. Hepatol. (Journal of hepatology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.

Hortense Chevalier, Angélique Vienot, Astrid Lièvre, Julien Edeline, Farid El Hajbi, Charlotte Peugniez, Dewi Vernerey, Aurélia Meurisse, Pascal Hammel, Cindy Neuzillet, Christophe Borg, Anthony Turpin,

BACKGROUND:Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil [5FU], folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de-escalation as a maintenance strategy for advanced pancreatic cancer. MATERIALS AND METHODS:This multicenter retrospective study was conducted from January 2011 to December 2018. FOLFIRINOX de-escalation was defined ... Read more >>

Oncologist (The oncologist)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Exposure-response analysis of Raltitrexed assessing liver toxicity.

Bernard Royer, Antonin Schmitt, Thierry Nguyen, Marie-Justine Paillard, Marine Jary, Martin Demarchi, Dewi Vernerey, Julie Henriques, Marion Jacquin, Christophe Borg, Stefano Kim,

AIM:Raltitrexed (RTX) is a thymidylate synthase inhibitor with large pharmacokinetics (PK) variability that can be administered in case of 5-fluorouracil (5FU) intolerance or dihydropyrimidine dehydrogenase deficiency. While it is a more potent thymidylate synthase inhibitor than 5FU, RTX failed to replace this drug for colorectal cancer patients, mainly due to ... Read more >>

Br J Clin Pharmacol (British journal of clinical pharmacology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity.

Marie Kroemer, Laurie Spehner, Lucie Vettoretti, Adeline Bouard, Guillaume Eberst, Sebastien Pili Floury, Gilles Capellier, Quentin Lepiller, Emeline Orillard, Laura Mansi, Anne-Laure Clairet, Virginie Westeel, Samuel Limat, Maxime Dubois, Léa Malinowski, Louis Bohard, Christophe Borg, Catherine Chirouze, Kevin Bouiller,

Adaptive Immune responses generated by SARS-CoV-2 virus in convalescent patients according to disease severity remain poorly characterized. To this end, we designed a prospective study (NCT04365322) that included 60 COVID-19 convalescent patients (1-month post infection) in two cohorts respectively entitled mild illness and severe pneumonia. The monitoring of peripheral immune ... Read more >>

J. Infect. (The Journal of infection)
[2020, :4816]

Cited: 0 times

View full text PDF listing >>



Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.

Josep Tabernero, Guillem Argiles, Alberto F Sobrero, Christophe Borg, Atsushi Ohtsu, Robert J Mayer, Loick Vidot, Shanti R Moreno Vera, Eric Van Cutsem,

BACKGROUND:The choice of treatment in patients with metastatic colorectal cancer (mCRC) is generally influenced by tumour and patient characteristics, treatment efficacy and tolerability, and quality of life. Better patient selection might lead to improved outcomes. METHODS:This post hoc exploratory analysis examined the effect of prognostic factors on outcomes in the ... Read more >>

ESMO Open (ESMO open)
[2020, 5(4):]

Cited: 0 times

View full text PDF listing >>



Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.

Charlotte Couchoud, Philippe Fagnoni, François Aubin, Virginie Westeel, Tristan Maurina, Antoine Thiery-Vuillemin, Claire Gerard, Marie Kroemer, Christophe Borg, Samuel Limat, Virginie Nerich,

OBJECTIVES:Scientific advances in the last decade have highlighted the use of immunotherapy, especially immune checkpoint inhibitors, to be an effective strategy in cancer therapy. However, these immunotherapeutic agents are expensive, and their use must take into account economic criteria. Thus, the objective of the present study was to systematically identify ... Read more >>

Cancer Immunol Immunother (Cancer immunology, immunotherapy : CII)
[2020, 69(10):1947-1958]

Cited: 0 times

View full text PDF listing >>



Molecular description of ANGPT2 associated colorectal carcinoma.

Marine Jary, Reyhan Hasanova, Angélique Vienot, Kamal Asgarov, Romain Loyon, Charline Tirole, Adeline Bouard, Emeline Orillard, Elodie Klajer, Stefano Kim, Julien Viot, Elise Colle, Olivier Adotevi, Olivier Bouché, Thierry Lecomte, Christophe Borg, Jean P Feugeas,

Angiopoietin-2 (ANGPT2) is a prognostic factor in metastatic colorectal cancer (CRC). Nevertheless, it remains to be elucidated which molecular characteristics make up the ANGPT2-related poor-prognosis CRC subset. Public transcriptomic datasets were collected from Gene Expression Omnibus GEO and with the TCGAbiolinks R-package for the TCGA. After appropriate normalization, differential expression ... Read more >>

Int. J. Cancer (International journal of cancer)
[2020, 147(7):2007-2018]

Cited: 0 times

View full text PDF listing >>



Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

Masatoshi Kudo, Peter R Galle, Josep M Llovet, Richard S Finn, Arndt Vogel, Kenta Motomura, Eric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min-Hua Jen, Nora Drove Ubreva, Ryan C Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X Zhu,

BACKGROUND & AIMS:Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc ... Read more >>

Liver Int. (Liver international : official journal of the International Association for the Study of the Liver)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, François Ghiringhelli, Éric François, Julien Taieb, Denis Smith, Christelle de la Fouchardière, Jérôme Desramé, Emmanuelle Samalin, Aurélie Parzy, Nabil Baba-Hamed, Olivier Bouché, David Tougeron, Laëtitia Dahan, Farid El Hajbi, Marion Jacquin, Magali Rebucci-Peixoto, Laurie Spehner, Véronique Vendrely, Dewi Vernerey, Christophe Borg,

BACKGROUND:Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epitopes-HPV02 trial. Antibodies targeting the checkpoint inhibitor (CKI) programmed cell death ... Read more >>

BMC Cancer (BMC cancer)
[2020, 20(1):352]

Cited: 0 times

View full text PDF listing >>



FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study.

Angélique Vienot, Hortense Chevalier, Clément Bolognini, Elisabeta Gherga, Elodie Klajer, Aurélia Meurisse, Marine Jary, Stefano Kim, Christelle d'Engremont, Thierry Nguyen, Fabien Calcagno, Hamadi Almotlak, Francine Fein, Meher Nasri, Syrine Abdeljaoued, Anthony Turpin, Christophe Borg, Dewi Vernerey,

BACKGROUND:FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal adenocarcinoma (aPDAC). FOLFOXIRI, a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil, has demonstrated efficacy and feasibility in colorectal cancer. AIM:To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical ... Read more >>

(World journal of gastrointestinal oncology)
[2020, 12(3):332-346]

Cited: 0 times

View full text PDF listing >>



The Fate of Th17 Cells is Shaped by Epigenetic Modifications and Remodeled by the Tumor Microenvironment.

Elodie Renaude, Marie Kroemer, Romain Loyon, Delphine Binda, Christophe Borg, Michaël Guittaut, Eric Hervouet, Paul Peixoto,

Th17 cells represent a subset of CD4+ T cells characterized by the master transcription factor RORγt and the production of IL-17. Epigenetic modifications such as post-translational histone modifications and DNA methylation play a key role in Th17 cell differentiation and high plasticity. Th17 cells are highly recruited in many types ... Read more >>

Int J Mol Sci (International journal of molecular sciences)
[2020, 21(5):]

Cited: 0 times

View full text PDF listing >>



Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer.

Adeline Dolly, Thierry Lecomte, Olivier Bouché, Christophe Borg, Eric Terrebonne, Jean-Yves Douillard, Romain Chautard, William Raoul, David Ternant, Julie Leger, Aurore Bleuzen, Jean-François Dumas, Stéphane Servais, Vickie E Baracos,

BACKGROUND:Changes in skeletal muscle mass (SMM), total adipose tissue mass (TAT) or bone mineral density (BMD) have been described in patients with cancer undergoing various treatments; simultaneous variations of all 3 tissues has not been reported. METHODS:Data were prospectively collected in a clinical study (NCT00489697) including patients with liver metastases ... Read more >>

Clin Nutr (Clinical nutrition (Edinburgh, Scotland))
[2020, :]

Cited: 0 times

View full text PDF listing >>



[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

Romain Cohen, Thomas Pudlarz, Marie-Line Garcia-Larnicol, Dewi Vernerey, Xavier Dray, Léa Clavel, Marine Jary, Guillaume Piessen, Aziz Zaanan, Thomas Aparicio, Christophe Louvet, Christophe Tournigand, Benoist Chibaudel, David Tougeron, Rosine Guimbaud, Jaafar Benouna, Antoine Adenis, Harry Sokol, Christophe Borg, Alex Duval, Magali Svrcek, Thierry André,

INTRODUCTION:Perioperative chemotherapy is the standard strategy for localized gastric cancers. Nevertheless, this strategy seems to be inefficient, if not deleterious, for patients with tumors harboring microsatellite instability (MSI) and/or mismatch repair deficiency (dMMR), a tumor phenotype predictive for the efficacy of immune checkpoint inhibitors (ICKi). AIM:The GERCOR NEONIPIGA single-arm phase ... Read more >>

Bull Cancer (Bulletin du cancer)
[2020, 107(4):438-446]

Cited: 0 times

View full text PDF listing >>



Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.

Philip A Philip, Jill Lacy, Fabienne Portales, Alberto Sobrero, Roberto Pazo-Cid, José L Manzano Mozo, Edward J Kim, Scot Dowden, Ahmed Zakari, Christophe Borg, Eric Terrebonne, Fernando Rivera, Javier Sastre, Venu Bathini, Daniel López-Trabada, Jamil Asselah, Muhammad Wasif Saif, Jack Shiansong Li, Teng Jin Ong, Thomas Nydam, Pascal Hammel,

BACKGROUND:Treatment options for patients with unresectable locally advanced pancreatic cancer are scarce. Results from a subanalysis of the phase 3 MPACT trial in metastatic pancreatic cancer suggested potential activity of nab-paclitaxel plus gemcitabine against locally advanced pancreatic cancer. The objective of this phase 2 trial was to evaluate safety and ... Read more >>

Lancet Gastroenterol Hepatol (The lancet. Gastroenterology & hepatology)
[2020, 5(3):285-294]

Cited: 0 times

View full text PDF listing >>



Metronomic cyclophosphamide induces regulatory T cells depletion and PSA-specific T cells reactivation in patients with biochemical recurrent prostate cancer.

Caroline Laheurte, Antoine Thiery-Vuillemin, Fabien Calcagno, Anna Legros, Harmonie Simonin, Laura Boullerot, Marion Jacquin, Thierry Nguyen, Guillaume Mouillet, Christophe Borg, Olivier Adotévi,

Biochemical recurrence (BCR) occurs in up to 40% of prostate cancer patients after prostatectomy. In our study, we performed an immune monitoring study in 20 prostate cancer patients with BCR previously treated with metronomic cyclophosphamide (mCTX). We observed a decrease of regulatory T cells (Tregs) from 2 months and this ... Read more >>

Int. J. Cancer (International journal of cancer)
[2020, 147(4):1199-1205]

Cited: 0 times

View full text PDF listing >>



Implementation and use of whole exome sequencing for metastatic solid cancer.

Manon Réda, Corentin Richard, Aurelie Bertaut, Julie Niogret, Thomas Collot, Jean David Fumet, Julie Blanc, Caroline Truntzer, Isabelle Desmoulins, Sylvain Ladoire, Audrey Hennequin, Laure Favier, Leila Bengrine, Julie Vincent, Alice Hervieu, Jean-Florian Guion Dusserre, Come Lepage, Pascal Foucher, Christophe Borg, Juliette Albuisson, Laurent Arnould, Sophie Nambot, Laurence Faivre, Romain Boidot, Francois Ghiringhelli,

BACKGROUND:Genomically-guided clinical trials are performed across different tumor types sharing genetic mutations, but trial organization remains complex. Here we address the feasibility and utility of routine somatic and constitutional exome analysis in metastatic cancer patients. METHODS:Exoma trial (NCT02840604) is a multicenter, prospective clinical trial. Eligible patients presented a metastatic cancer ... Read more >>

EBioMedicine (EBioMedicine)
[2020, 51:102624]

Cited: 0 times

View full text PDF listing >>



Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study.

Violaine Randrian, Antoine Adenis, Jérôme Desrame, Emilie Barbier, Frédéric Di Fiore, Astrid Lièvre, Laetitia Dahan, Pierre Laurent-Puig, Laurent Mineur, Gilles Breysacher, Guillaume Roquin, Samy Louafi, Anthony Lopez, Christophe Louvet, Christophe Borg, Jean Philippe Metges, Roger Faroux, Lila Gaba, Sylvain Manfredi, David Tougeron,

Half of patients newly diagnosed with esophageal squamous cell cancer (ESCC) have metastatic disease (mESCC) and therefore a poor prognosis. Furthermore, half of patients with initial loco-regional disease present disease recurrence after surgery and/or chemoradiation. In mESCC, the recommended first-line treatment combines 5-fluorouracil and cisplatin, although this has not been ... Read more >>

Dig Liver Dis (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver)
[2020, 52(3):347-350]

Cited: 0 times

View full text PDF listing >>



Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non-Small Cell Lung Cancer.

Elodie Lauret Marie Joseph, Caroline Laheurte, Marine Jary, Laura Boullerot, Kamal Asgarov, Eléonore Gravelin, Adeline Bouard, Laurie Rangan, Magalie Dosset, Christophe Borg, Olivier Adotévi,

Myeloid-derived suppressor cells (MDSC) promote immunosuppression and are a target in the field of immuno-oncology. Accumulation of MDSCs is associated with poor prognosis and resistance to immunotherapy for several cancers. Here, we describe an accumulation of a subset of circulating monocytic MDSCs (M-MDSC) overexpressing TIE2, the receptor for angiopoietin-2 (ANGPT2), ... Read more >>

Cancer Immunol Res (Cancer immunology research)
[2020, 8(2):268-279]

Cited: 1 time

View full text PDF listing >>



Development of Ovarian Tissue Autograft to Restore Ovarian Function: Protocol for a French Multicenter Cohort Study.

Jean-Baptiste Pretalli, Sophie Frontczak Franck, Lionel Pazart, Christophe Roux, Clotilde Amiot, ,

BACKGROUND:Sterility is a major late effect of radiotherapy and chemotherapy treatments. Iatrogenic sterility is often permanent and greatly impacts long-term quality of life. Ovarian tissue cryopreservation (OTC) performed before gonadotoxic treatments with subsequent autograft is a method of fertility preservation available for girls and women. Its application in prepubertal girls ... Read more >>

JMIR Res Protoc (JMIR research protocols)
[2019, 8(9):e12944]

Cited: 0 times

View full text PDF listing >>



[Radiologic response assessment in metastatic colorectal cancers].

Achille Fabre, Nicolas Badet, Paul Calame, Eric Delabrousse, Mylène Wespiser, Celia Turco, Christophe Borg, Marine Jary,

The increasing indications of cytostatic biotherapies and the improvement in metastatic surgery have profoundly changed the management of metastatic colorectal cancer (mCRC) patients. Then the development of prognostic and predictive scores would be useful to stratify the treatments. Tumor radiological measurement is crucial to estimate treatment efficacy, and to predict ... Read more >>

Bull Cancer (Bulletin du cancer)
[2019, 106(11):1029-1038]

Cited: 0 times

View full text PDF listing >>



CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Jeanne Galaine, Célia Turco, Charline Vauchy, Bernard Royer, Patricia Mercier-Letondal, Lise Queiroz, Romain Loyon, Virginie Mouget, Romain Boidot, Caroline Laheurte, Zaher Lakkis, Marine Jary, Olivier Adotévi, Christophe Borg, Yann Godet,

Immune checkpoint blockade has proven its efficacy in hypermutated subtypes of metastatic colorectal cancers (mCRC). Immunogenic potential can also be observed with conventional chemotherapies, but this property has never been explored thoroughly in CRC patients. The CRC therapeutic arsenal includes oxaliplatin, a well-characterized platinum drug already described as immunogenic. Here, ... Read more >>

Int. J. Cancer (International journal of cancer)
[2019, 145(11):3112-3125]

Cited: 1 time

View full text PDF listing >>



Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Romain Loyon, Marine Jary, Bérengère Salomé, Alejandra Gomez-Cadena, Jeanne Galaine, Marie Kroemer, Pedro Romero, Sara Trabanelli, Olivier Adotévi, Christophe Borg, Camilla Jandus,

Several distinct innate lymphoid cell (ILC) populations have been recently identified and shown to play a critical role in the immediate immune defense. In the context of tumors, there is evidence to support a dual role for ILCs with pro- or antitumor effects, depending on the ILC subset and the ... Read more >>

Front Immunol (Frontiers in immunology)
[2019, 10:2121]

Cited: 4 times

View full text PDF listing >>



Comparison of Molecular and Histologic Ultrastaging Methods in Sentinel Lymph Node Analysis from Clinical Stage II Colon Cancers.

Olivier Deroo, Zaher Lakkis, Brice Paquette, David Grand, Franck Monnien, Sophie Felix, Christophe Borg, Bruno Heyd, Stefano Kim, Séverine Valmary-Degano,

Various studies have demonstrated that occult metastases may be present in patients with clinical stage II colon cancer. The objective of this prospective investigation was to compare the performance of molecular analysis and histologic ultrastaging in detecting occult metastases in sentinel lymph nodes (SLNs). SLNs were collected ex vivo during ... Read more >>

Appl. Immunohistochem. Mol. Morphol. (Applied immunohistochemistry & molecular morphology : AIMM)
[2019, 27(7):e65-e70]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.9952 s